AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

ALISO VIEJO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported the grant of restricted stock units (“RSUs”) covering 150,000 shares of the Company’s common stock to one newly hired non-executive employee of the Company. The award was approved by the Company’s Compensation Committee of the Board of Directors on October 5, 2026 under the Company’s 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of the Company. The RSUs vest in four equal installments, 25% on each annual anniversary of March 9, 2026. The award is subject to the terms and conditions of the Inducement Plan and the terms and conditions of the RSU agreement covering the grant. The RSUs were granted as a material inducement to the employee’s entering into employment with the Company in accordance with Section 711 of NYSE American LLC Company Guide.

About AEON Biopharma

AEON Biopharma is a biopharmaceutical company pursuing full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau®. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and the European Medicines Agency for the manufacture of certain third-party botulinum toxin products. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.

Contacts

Investor Contact:
Hershel Berry
Blueprint Life Science Group
hberry@bplifescience.com 

Source: AEON Biopharma


The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center